Jabrane Karkouri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jabrane Karkouri has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Christopher T. Rodgers
Department of Clinical Neurosciences University of Cambridge Cambridge UK
6 shared publications Alexandra Constantinou
Wolfson Brain Imaging Centre University of Cambridge Cambridge UK
2 shared publicationsBrandon Tramm
Virtumed, LLC Minneapolis Minnesota USA
2 shared publicationsCarina Graf
Wolfson Brain Imaging Centre University of Cambridge Cambridge UK
2 shared publicationsDaniel Atkinson
Wolfson Brain Imaging Centre University of Cambridge Cambridge UK
2 shared publicationsDennis Klomp
UMC Utrecht, Utrecht, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Springer Nature in Research Square
Magnetic Resonance Spectroscopy and Metabolic MRI in Epilepsy: A Systematic Review and Quantitative Synthesis of Neurochemical Biomarkers and Clinical Applications
Background: Since the introduction of proton magnetic resonance spectroscopy (¹H-MRS) in epilepsy research in the 1980s, metabolic MRI has provided unique insights into the neurochemical alterations underlying epilepsy. However, evidence has remained fragmented across imaging modalities, epilepsy syndromes, and clinical applications. We systematically reviewed the literature to define the metabolic phenotype of epilepsy and evaluate the evolving role of metabolic MRI in epilepsy research and clinical practice. Methods: Following PRISMA 2020 guidelines, PubMed and Scopus were systematically searched through April 2026 for original human studies investigating metabolic MRI in epilepsy. Two reviewers independently performed study selection, data extraction, and quality assessment. Findings were synthesized through structured qualitative evidence, supported by integrated methodological, scientometric, tabular, and visual analyses. Results: A total of 298 studies were included. Focal epilepsy demonstrated widespread alterations involving N-acetyl aspartate, glutamate, Gamma-aminobutyric acid, choline-containing compounds, myo-inositol, lactate, and other metabolites across epileptogenic and brain networks. Generalized epilepsy was characterized by predominantly bilateral and thalamo-cortical metabolic abnormalities, whereas tumor-associated epilepsy showed distinct metabolic alterations within tumors and the peritumoral zone. Treatment and prognostic studies demonstrated metabolite-specific changes following pharmacological and surgical interventions, and emerging metabolic MRI techniques provided complementary information on bioenergetics, ionic homeostasis, glutamatergic cycling, and metabolic flux. Conclusions: The available evidence supports epilepsy as a disorder of distributed metabolic networks that share a common signature of neuronal dysfunction while exhibiting syndrome-specific alterations in neurotransmission, gliosis, and energy metabolism. Complementary metabolic MRI techniques provide distinct biological information, but their clinical translation will require methodological harmonization and multimodal integration.
- 3 November 2026
- Published by Springer Nature in Research Square
Open AccessMagnetic Resonance Spectroscopy and Metabolic MRI in Epilepsy: A Systematic Review and Quantitative Synthesis of Neurochemical Biomarkers and Clinical Applications
Background: Since the introduction of proton magnetic resonance spectroscopy (¹H-MRS) in epilepsy research in the 1980s, metabolic MRI has provided unique insights into the neurochemical alterations underlying epilepsy. However, evidence has remained fragmented across imaging modalities, epilepsy syndromes, and clinical applications. We systematically reviewed the literature to define the metabolic phenotype of epilepsy and evaluate the evolving role of metabolic MRI in epilepsy research and clinical practice. Methods: Following PRISMA 2020 guidelines, PubMed and Scopus were systematically searched through April 2026 for original human studies investigating metabolic MRI in epilepsy. Two reviewers independently performed study selection, data extraction, and quality assessment. Findings were synthesized through structured qualitative evidence, supported by integrated methodological, scientometric, tabular, and visual analyses. Results: A total of 298 studies were included. Focal epilepsy demonstrated widespread alterations involving N-acetyl aspartate, glutamate, Gamma-aminobutyric acid, choline-containing compounds, myo-inositol, lactate, and other metabolites across epileptogenic and brain networks. Generalized epilepsy was characterized by predominantly bilateral and thalamo-cortical metabolic abnormalities, whereas tumor-associated epilepsy showed distinct metabolic alterations within tumors and the peritumoral zone. Treatment and prognostic studies demonstrated metabolite-specific changes following pharmacological and surgical interventions, and emerging metabolic MRI techniques provided complementary information on bioenergetics, ionic homeostasis, glutamatergic cycling, and metabolic flux. Conclusions: The available evidence supports epilepsy as a disorder of distributed metabolic networks that share a common signature of neuronal dysfunction while exhibiting syndrome-specific alterations in neurotransmission, gliosis, and energy metabolism. Complementary metabolic MRI techniques provide distinct biological information, but their clinical translation will require methodological harmonization and multimodal integration.
- Open Access
Regional cardiac 31P-MRSI at 7T: detection of spatially heterogeneous patterns of myocardial energetic impairment
Background The phosphocreatine-to-ATP ratio (PCr/ATP), measurable by 31P magnetic resonance spectroscopic imaging (31P-MRSI), is a sensitive marker of myocardial energetic reserve. Regional energetic-mechanical coupling, evaluable only per-segment to avoid confounding from spatially heterogeneous disease, represents an important target for cardiac metabolic trials. We extend our previously validated 7T regional 31P-MRSI approach to patients with cardiovascular disease. Methods Twenty-one participants underwent same-day 7T 31P-MRSI and 3T CMR: 9 healthy volunteers, 4 with type 2 diabetes, 5 with heart failure, and 3 with ischaemic cardiomyopathy. PCr/ATP was mapped across six mid-ventricular AHA segments. Ejection fraction, global longitudinal strain, peak filling rate, and regional circumferential and radial strain were derived from 3T CMR. Group differences were assessed by Kruskal-Wallis test with Bonferroni-corrected pairwise comparisons; segment-level associations by per-segment Spearman correlation and linear mixed effects models. Results PCr/ATP differed significantly across groups (p = 0.005, eta^2 = 0.58), ranging from 1.78 +/- 0.21 in healthy volunteers to 1.10 +/- 0.28 in heart failure. Mean PCr/ATP correlated with ejection fraction (rs = 0.65, p = 0.002), global longitudinal strain (rs = -0.63, p < 0.001), and peak filling rate (rs = 0.52, p = 0.023). Segment-level energetic-mechanical coupling was significant in the anteroseptal and inferoseptal segments (circumferential strain rs = -0.49 to -0.56; radial strain rs = 0.43 to 0.57, all p < 0.05), with no significant associations in other segments, consistent with a displacement-related measurement quality gradient. In ischaemic patients, PCr/ATP was significantly lower in infarct segments (0.79 +/- 0.20) than remote myocardium (1.33 +/- 0.22, p = 0.008, r = 0.62). All three ischaemic patients demonstrated remote PCr/ATP below the healthy volunteer median, with two below the 5th percentile (rank-sum p = 0.018; Fisher p = 0.045). Conclusions Regional 7T 31P-MRSI detects segment-level energetic differences across cardiovascular disease states and reveals spatially specific energetic-mechanical coupling confined to the septal segments in the current ungated acquisition. Energetic impairment in ischaemic cardiomyopathy extends into structurally preserved remote myocardium. These findings support larger studies using regional 31P-MRSI to investigate regional energetic-mechanical coupling as a target for metabolic cardiac therapies.
Open AccessRegional cardiac 31P-MRSI at 7T: detection of spatially heterogeneous patterns of myocardial energetic impairment
Background The phosphocreatine-to-ATP ratio (PCr/ATP), measurable by 31P magnetic resonance spectroscopic imaging (31P-MRSI), is a sensitive marker of myocardial energetic reserve. Regional energetic-mechanical coupling, evaluable only per-segment to avoid confounding from spatially heterogeneous disease, represents an important target for cardiac metabolic trials. We extend our previously validated 7T regional 31P-MRSI approach to patients with cardiovascular disease. Methods Twenty-one participants underwent same-day 7T 31P-MRSI and 3T CMR: 9 healthy volunteers, 4 with type 2 diabetes, 5 with heart failure, and 3 with ischaemic cardiomyopathy. PCr/ATP was mapped across six mid-ventricular AHA segments. Ejection fraction, global longitudinal strain, peak filling rate, and regional circumferential and radial strain were derived from 3T CMR. Group differences were assessed by Kruskal-Wallis test with Bonferroni-corrected pairwise comparisons; segment-level associations by per-segment Spearman correlation and linear mixed effects models. Results PCr/ATP differed significantly across groups (p = 0.005, eta^2 = 0.58), ranging from 1.78 +/- 0.21 in healthy volunteers to 1.10 +/- 0.28 in heart failure. Mean PCr/ATP correlated with ejection fraction (rs = 0.65, p = 0.002), global longitudinal strain (rs = -0.63, p < 0.001), and peak filling rate (rs = 0.52, p = 0.023). Segment-level energetic-mechanical coupling was significant in the anteroseptal and inferoseptal segments (circumferential strain rs = -0.49 to -0.56; radial strain rs = 0.43 to 0.57, all p < 0.05), with no significant associations in other segments, consistent with a displacement-related measurement quality gradient. In ischaemic patients, PCr/ATP was significantly lower in infarct segments (0.79 +/- 0.20) than remote myocardium (1.33 +/- 0.22, p = 0.008, r = 0.62). All three ischaemic patients demonstrated remote PCr/ATP below the healthy volunteer median, with two below the 5th percentile (rank-sum p = 0.018; Fisher p = 0.045). Conclusions Regional 7T 31P-MRSI detects segment-level energetic differences across cardiovascular disease states and reveals spatially specific energetic-mechanical coupling confined to the septal segments in the current ungated acquisition. Energetic impairment in ischaemic cardiomyopathy extends into structurally preserved remote myocardium. These findings support larger studies using regional 31P-MRSI to investigate regional energetic-mechanical coupling as a target for metabolic cardiac therapies.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Exploiting sparse spectrum to accelerate spiral magnetic resonance spectroscopic imaging : method, simulation and applications to the functional exploration of skeletal muscle
Exploiter la parcimonie des spectres pour accélérer l'imagerie spectroscopique spirale par résonance magnétique : méthode, simulation et applications à l'exploration fonctionnelle du muscle squelettique: La quantification du métabolisme musculaire énergétique et de la capacité mitochondriale est d'un intérêt crucial pour étudier les troubles musculaires, les maladies métaboliques ou cardiovasculaires comme la myopathie mitochondriale, le diabète ou les maladies artérielles périphériques. La spectroscopie 31P est un moyen non invasif de monitorer le métabolisme énergétique et les concentrations dynamiques de métabolites phosphorylés pendant ou après un exercice et fournit des informations sur la capacité mitochondriale et oxydative du muscle squelettique. L'évaluation du métabolisme énergétique par spectroscopie 31P peut se faire par spectroscopie non localisée, spectroscopie monovoxel et imagerie spectroscopique par résonance magnétique (MRSI). Dans la pratique clinique, la spectroscopie 31P non localisée est généralement réalisée, ce qui empêche de mesurer les informations métaboliques de différents muscles individuellement, et une information moyenne résultant du muscle entier est collectée en une seule fois par la bobine de surface utilisée pour l'expérience. L'utilisation de la spectroscopie 31P localisée permettrait d'accéder à des informations spatialement résolues et de motiver le développement de nouvelles séquences intégrant les développements techniques les plus avancés. L'imagerie spectroscopique par résonance magnétique (ISRM) disponible dans les systèmes cliniques a un temps d'acquisition très long qui limite son utilisation clinique à l'acquisition statique, alors que ce qui est d’intérêt est essentiellement la capacité à mesurer dynamiquement les variations de concentration des métabolites phosphorylés au cours d’un protocole d'exercice. Les développements méthodologiques sur l’ISRM réalisés dans le cadre de cette thèse, se sont attaqués précisément à réduire le temps d'acquisition, en vue d’applications cliniques. Une méthode d'acquisition ISRM rapide a donc été développée, impliquant un échantillonnage non cartésien dans l'espace k (échantillonnage en spirale), couplé à un sous-échantillonnage intelligent de la dimension temporelle, exploitant la connaissance a priori de la parcimonie du support spectral et une estimation par moindres carrés pour la reconstruction du signal. Cette méthode a été validée à l'aide de simulations et mise en œuvre dans un système IRM, optimisée puis testée in vivo sur le muscle du mollet pour des applications ISRM 1H et 31P. Des applications dynamiques 31P ont également été réalisées à 3T et l'utilisation de la séquence sous-échantillonnée CSI spiral développée a montré qu'elle était capable de révéler les changements dynamiques attendus dans le PCr. La quantification du signal nous a permis en outre d'accéder à la capacité mitochondriale, avec une résolution temporelle dynamique deux fois supérieure à celle du cas ISRM spiral avec échantillonnage régulier, et une résolution temporelle similaire à celle de l’ISRM non localisée utilisée conventionnellement. Ces développements sont d'un intérêt crucial pour une évaluation spatialement résolue de la capacité mitochondriale au sein de différents muscles ; c'est-à-dire pour mettre en évidence des altérations musculaires individuelles liées à des dommages spécifiques ou des différences de consommation d'énergie entre les différents chefs musculaires pendant l'exercice. Des améliorations de séquence sur la spectroscopie 31P localisée 1D ont également été intégrées dans un protocole clinique en cours, afin, à terme, d’appliquer les développements de séquence réalisés pendant cette thèse à un contexte clinique. D'abord testé sur des volontaires sains pour la reproductibilité, le protocole implique des patients qui souffrent d'artériopathie de la jambe inférieure. L'objectif était d'évaluer la capacité mitochondriale de ces patients avant et après une revascularisation de l'artère endommagée. Les résultats ont montré une amélioration significative de la capacité mitochondriale après revascularisation
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Exploiting sparse spectrum to accelerate spiral magnetic resonance spectroscopic imaging : method, simulation and applications to the functional exploration of skeletal muscle
Exploiter la parcimonie des spectres pour accélérer l'imagerie spectroscopique spirale par résonance magnétique : méthode, simulation et applications à l'exploration fonctionnelle du muscle squelettique: La quantification du métabolisme musculaire énergétique et de la capacité mitochondriale est d'un intérêt crucial pour étudier les troubles musculaires, les maladies métaboliques ou cardiovasculaires comme la myopathie mitochondriale, le diabète ou les maladies artérielles périphériques. La spectroscopie 31P est un moyen non invasif de monitorer le métabolisme énergétique et les concentrations dynamiques de métabolites phosphorylés pendant ou après un exercice et fournit des informations sur la capacité mitochondriale et oxydative du muscle squelettique. L'évaluation du métabolisme énergétique par spectroscopie 31P peut se faire par spectroscopie non localisée, spectroscopie monovoxel et imagerie spectroscopique par résonance magnétique (MRSI). Dans la pratique clinique, la spectroscopie 31P non localisée est généralement réalisée, ce qui empêche de mesurer les informations métaboliques de différents muscles individuellement, et une information moyenne résultant du muscle entier est collectée en une seule fois par la bobine de surface utilisée pour l'expérience. L'utilisation de la spectroscopie 31P localisée permettrait d'accéder à des informations spatialement résolues et de motiver le développement de nouvelles séquences intégrant les développements techniques les plus avancés. L'imagerie spectroscopique par résonance magnétique (ISRM) disponible dans les systèmes cliniques a un temps d'acquisition très long qui limite son utilisation clinique à l'acquisition statique, alors que ce qui est d’intérêt est essentiellement la capacité à mesurer dynamiquement les variations de concentration des métabolites phosphorylés au cours d’un protocole d'exercice. Les développements méthodologiques sur l’ISRM réalisés dans le cadre de cette thèse, se sont attaqués précisément à réduire le temps d'acquisition, en vue d’applications cliniques. Une méthode d'acquisition ISRM rapide a donc été développée, impliquant un échantillonnage non cartésien dans l'espace k (échantillonnage en spirale), couplé à un sous-échantillonnage intelligent de la dimension temporelle, exploitant la connaissance a priori de la parcimonie du support spectral et une estimation par moindres carrés pour la reconstruction du signal. Cette méthode a été validée à l'aide de simulations et mise en œuvre dans un système IRM, optimisée puis testée in vivo sur le muscle du mollet pour des applications ISRM 1H et 31P. Des applications dynamiques 31P ont également été réalisées à 3T et l'utilisation de la séquence sous-échantillonnée CSI spiral développée a montré qu'elle était capable de révéler les changements dynamiques attendus dans le PCr. La quantification du signal nous a permis en outre d'accéder à la capacité mitochondriale, avec une résolution temporelle dynamique deux fois supérieure à celle du cas ISRM spiral avec échantillonnage régulier, et une résolution temporelle similaire à celle de l’ISRM non localisée utilisée conventionnellement. Ces développements sont d'un intérêt crucial pour une évaluation spatialement résolue de la capacité mitochondriale au sein de différents muscles ; c'est-à-dire pour mettre en évidence des altérations musculaires individuelles liées à des dommages spécifiques ou des différences de consommation d'énergie entre les différents chefs musculaires pendant l'exercice. Des améliorations de séquence sur la spectroscopie 31P localisée 1D ont également été intégrées dans un protocole clinique en cours, afin, à terme, d’appliquer les développements de séquence réalisés pendant cette thèse à un contexte clinique. D'abord testé sur des volontaires sains pour la reproductibilité, le protocole implique des patients qui souffrent d'artériopathie de la jambe inférieure. L'objectif était d'évaluer la capacité mitochondriale de ces patients avant et après une revascularisation de l'artère endommagée. Les résultats ont montré une amélioration significative de la capacité mitochondriale après revascularisation
- Open Access
- 23 February 2026
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 95 (6) , 3077-3094
Absolute Quantification of Brain Deuterium Metabolic Imaging in Healthy Volunteers and Glioblastoma Patients at 7T
Purpose: We present a method for absolute quantification of deuterated metabolites in vivo at 7T. We describe acquisition protocols and an analysis pipeline compatible with 7T Terra MRIs. We apply them using a 2 H/ 1 H receive array in healthy volunteers and glioblastoma patients. Methods: B 1 + /B 1 − maps from multiple CSI scans in a uniform phantom were used to derive calibrated coil weights for absolute quantification. We validated this in phantoms with known deuterated compounds. 2 H MRSI was performed in twelve healthy volunteers (two post‐[6,6‐ 2 H 2 ]‐glucose) and five treatment‐naive glioblastoma patients (all post‐[6,6‐ 2 H 2 ]‐glucose). Spectra were fitted with OXSA. We compared Glx/Lac between tumor and normal‐appearing brain using linear mixed‐effects models. Results: Measured B 1 + maps were 0.82 ± 0.19 μT/√W across the whole phantom. Natural abundance deuterium in water was 8.96 ± 0.7 mmol/L. Absolute maps of HDO, Glc, Glx, and Lac were acquired following [6,6‐ 2 H 2 ]glucose. Rate maps showed higher Lac production in tumors (2.3 μmol/L/min, SE = 0.87) compared with normal‐appearing regions (1.0 μmol/L/min, SE = 0.36; p < 0.01) and healthy brain (0.5 μmol/L/min, SE = 0.17; p < 0.01). Glx production was lower in tumors (3.8 μmol/L/min, SE = 0.44) relative to normal‐appearing contralateral regions (6.0 μmol/L/min, SE = 0.36; p < 0.001) and healthy brain (9.2 μmol/L/min, SE = 0.61; p < 0.001). Conclusion: We demonstrate robust absolute quantification for human 7T DMI. Glioblastoma tumors showed elevated Lac and reduced Glx labeling relative to normal brain, with inter‐patient heterogeneity consistent with an existence of different metabolic subtypes.
- 23 February 2026
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 95 (6) , 3077-3094
Open AccessAbsolute Quantification of Brain Deuterium Metabolic Imaging in Healthy Volunteers and Glioblastoma Patients at 7T
Purpose: We present a method for absolute quantification of deuterated metabolites in vivo at 7T. We describe acquisition protocols and an analysis pipeline compatible with 7T Terra MRIs. We apply them using a 2 H/ 1 H receive array in healthy volunteers and glioblastoma patients. Methods: B 1 + /B 1 − maps from multiple CSI scans in a uniform phantom were used to derive calibrated coil weights for absolute quantification. We validated this in phantoms with known deuterated compounds. 2 H MRSI was performed in twelve healthy volunteers (two post‐[6,6‐ 2 H 2 ]‐glucose) and five treatment‐naive glioblastoma patients (all post‐[6,6‐ 2 H 2 ]‐glucose). Spectra were fitted with OXSA. We compared Glx/Lac between tumor and normal‐appearing brain using linear mixed‐effects models. Results: Measured B 1 + maps were 0.82 ± 0.19 μT/√W across the whole phantom. Natural abundance deuterium in water was 8.96 ± 0.7 mmol/L. Absolute maps of HDO, Glc, Glx, and Lac were acquired following [6,6‐ 2 H 2 ]glucose. Rate maps showed higher Lac production in tumors (2.3 μmol/L/min, SE = 0.87) compared with normal‐appearing regions (1.0 μmol/L/min, SE = 0.36; p < 0.01) and healthy brain (0.5 μmol/L/min, SE = 0.17; p < 0.01). Glx production was lower in tumors (3.8 μmol/L/min, SE = 0.44) relative to normal‐appearing contralateral regions (6.0 μmol/L/min, SE = 0.36; p < 0.001) and healthy brain (9.2 μmol/L/min, SE = 0.61; p < 0.001). Conclusion: We demonstrate robust absolute quantification for human 7T DMI. Glioblastoma tumors showed elevated Lac and reduced Glx labeling relative to normal brain, with inter‐patient heterogeneity consistent with an existence of different metabolic subtypes.
- Open Access
- 8 December 2025
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 95 (5) , 2508-2514
Repeatability of Rapid Human Cardiac Phosphorus MRSI ( 31 P ‐ MRSI ) Using Concentric Ring Trajectory Readouts at 7 T
Purpose: PCr/ATP ratio is determined at 7 T typically using Fourier‐transform based magnetic resonance spectroscopic imaging sequences (FT‐MRSI). These sequences require acquisition times longer than desirable for inclusion in cardiac clinical trials. Concentric ring trajectory (CRT‐MRSI) has been described as an accelerated alternative k‐space sampling method. In this work we aim to establish the inter‐ and intra‐session repeatability of three different CRT protocols and compare their voxel‐based PCr/ATP ratios to compartment‐based PCr/ATP values extracted with spectroscopy using a linear algebraic model (SLAM) method. Methods: Seven healthy volunteers were scanned twice on two different days. Each time a 6.5‐min 3D FT‐MRSI acquisition with 10 × 10 × 10 resolution was followed by a 2.5‐min CRT‐MRSI with matched resolution, a 1.5‐min CRT‐MRSI with matched resolution, and a 6.9‐min CRT‐MRSI with 12 × 12 × 12 resolution. Spectra from a mid‐septal voxel and the cardiac compartment were fitted with the OXSA toolbox. PCr/ATP ratio was quantified for inter‐ and intra‐session repeatability analysis. Results: Paired repeated measurements were not significantly different within subjects. Good inter‐ and intra‐session agreement was observed between FT‐MRSI and each CRT‐MRSI protocol. CRT‐MRSI protocols all had larger coefficients of repeatability (CoR) than FT‐MRSI. CRT‐SLAM‐based PCr/ATP values had lower CoR than voxel‐based data except for 2.5‐min CRT‐SLAM, and high‐resolution CRT‐SLAM had lower inter‐session CoR compared to FT‐MRSI (1.42 vs. 2.21). Conclusion: We established the repeatability of CRT‐MRSI‐based PCr/ATP values and showed higher SNR and lower CoR for CRT‐SLAM. Our findings allow shorter 31 P MRS acquisition times and the use of more advanced energetics‐probing techniques in clinical studies.
- 8 December 2025
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 95 (5) , 2508-2514
Open AccessRepeatability of Rapid Human Cardiac Phosphorus MRSI ( 31 P ‐ MRSI ) Using Concentric Ring Trajectory Readouts at 7 T
Purpose: PCr/ATP ratio is determined at 7 T typically using Fourier‐transform based magnetic resonance spectroscopic imaging sequences (FT‐MRSI). These sequences require acquisition times longer than desirable for inclusion in cardiac clinical trials. Concentric ring trajectory (CRT‐MRSI) has been described as an accelerated alternative k‐space sampling method. In this work we aim to establish the inter‐ and intra‐session repeatability of three different CRT protocols and compare their voxel‐based PCr/ATP ratios to compartment‐based PCr/ATP values extracted with spectroscopy using a linear algebraic model (SLAM) method. Methods: Seven healthy volunteers were scanned twice on two different days. Each time a 6.5‐min 3D FT‐MRSI acquisition with 10 × 10 × 10 resolution was followed by a 2.5‐min CRT‐MRSI with matched resolution, a 1.5‐min CRT‐MRSI with matched resolution, and a 6.9‐min CRT‐MRSI with 12 × 12 × 12 resolution. Spectra from a mid‐septal voxel and the cardiac compartment were fitted with the OXSA toolbox. PCr/ATP ratio was quantified for inter‐ and intra‐session repeatability analysis. Results: Paired repeated measurements were not significantly different within subjects. Good inter‐ and intra‐session agreement was observed between FT‐MRSI and each CRT‐MRSI protocol. CRT‐MRSI protocols all had larger coefficients of repeatability (CoR) than FT‐MRSI. CRT‐SLAM‐based PCr/ATP values had lower CoR than voxel‐based data except for 2.5‐min CRT‐SLAM, and high‐resolution CRT‐SLAM had lower inter‐session CoR compared to FT‐MRSI (1.42 vs. 2.21). Conclusion: We established the repeatability of CRT‐MRSI‐based PCr/ATP values and showed higher SNR and lower CoR for CRT‐SLAM. Our findings allow shorter 31 P MRS acquisition times and the use of more advanced energetics‐probing techniques in clinical studies.
- Open Access
Absolute quantification of brain deuterium metabolic imaging in healthy volunteers and glioblastoma patients at 7T
Purpose: We present a method for absolute quantification of deuterated metabolites in vivo at 7T. We describe acquisition protocols and an analysis pipeline compatible with 7T Terra MRIs, and apply these using a 2 H/ 1 H receive array in healthy volunteers and glioblastoma patients. Methods: B 1 + /B 1 − maps from multiple CSI scans in a uniform phantom were used to derive calibrated coil weights for absolute quantification, validated in phantoms with known deuterated compounds. 2 H MRSI was performed in twelve healthy volunteers (two post-[6,6- 2 H 2 ]-glucose) and five glioblastoma patients (all post-[6,6- 2 H 2 ]-glucose). Spectra were fitted with OXSA, and Glx/Lac compared between tumor and normal-appearing brain using linear mixed-effects models. Results: Measured B 1 + maps were across the whole phantom. Natural abundance deuterium in water was 8.96 ± 0.7 mmol/L. Absolute maps of HDO, Glc, Glx, and Lac were acquired following [6,6- 2 H 2 ]glucose. Rate maps showed higher Lac production in tumors (2.3 μmol/L/min, SE = 0.87) compared with normal-appearing regions (1.0 μmol/L/min, SE = 0.36; p < 0.01) and healthy brain (0.5 μmol/L/min, SE = 0.17; p < 0.01). Glx production was lower in tumors (3.8 μmol/L/min, SE = 0.44) relative to normal-appearing regions (6.0 μmol/L/min, SE = 0.36; p < 0.001) and healthy brain (9.2 μmol/L/min, SE = 0.61; p < 0.001). Conclusion: We demonstrate robust absolute quantification for human 7T DMI. Glioblastomas showed elevated Lac and reduced Glx labeling relative to normal brain, with inter-patient heterogeneity consistent with an existence of different metabolic subtypes.
Open AccessAbsolute quantification of brain deuterium metabolic imaging in healthy volunteers and glioblastoma patients at 7T
Purpose: We present a method for absolute quantification of deuterated metabolites in vivo at 7T. We describe acquisition protocols and an analysis pipeline compatible with 7T Terra MRIs, and apply these using a 2 H/ 1 H receive array in healthy volunteers and glioblastoma patients. Methods: B 1 + /B 1 − maps from multiple CSI scans in a uniform phantom were used to derive calibrated coil weights for absolute quantification, validated in phantoms with known deuterated compounds. 2 H MRSI was performed in twelve healthy volunteers (two post-[6,6- 2 H 2 ]-glucose) and five glioblastoma patients (all post-[6,6- 2 H 2 ]-glucose). Spectra were fitted with OXSA, and Glx/Lac compared between tumor and normal-appearing brain using linear mixed-effects models. Results: Measured B 1 + maps were across the whole phantom. Natural abundance deuterium in water was 8.96 ± 0.7 mmol/L. Absolute maps of HDO, Glc, Glx, and Lac were acquired following [6,6- 2 H 2 ]glucose. Rate maps showed higher Lac production in tumors (2.3 μmol/L/min, SE = 0.87) compared with normal-appearing regions (1.0 μmol/L/min, SE = 0.36; p < 0.01) and healthy brain (0.5 μmol/L/min, SE = 0.17; p < 0.01). Glx production was lower in tumors (3.8 μmol/L/min, SE = 0.44) relative to normal-appearing regions (6.0 μmol/L/min, SE = 0.36; p < 0.001) and healthy brain (9.2 μmol/L/min, SE = 0.61; p < 0.001). Conclusion: We demonstrate robust absolute quantification for human 7T DMI. Glioblastomas showed elevated Lac and reduced Glx labeling relative to normal brain, with inter-patient heterogeneity consistent with an existence of different metabolic subtypes.
- Open Access
- 23 March 2025
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 94 (2) , 480-496
Regionally resolved cardiac metabolism using a dipole‐loop array coil for 7 T 31 P ‐ MRSI
Purpose: We introduce a novel commercial phosphorus‐31 ( 31 P) dipole‐loop array coil, describing the coil hardware and testing its performance on phantoms. We used this coil to assess cardiac metabolism per region in healthy volunteers. Methods: B 1 + field maps were simulated and compared to maps measured with a set of CSI sequences with varying voltages. Seventeen volunteers were scanned with 7 T phosphorus‐31 magnetic resonance spectroscopic imaging ( 31 P‐MRSI). Reproducibility was assessed in nine of these volunteers. Strain was measured for six of these volunteers at 3 T. Results: Blood‐ and saturation‐corrected Phosphocreatine/γ‐adenosine triphosphate (PCr/ATP) ratios were measured for four regions of the left ventricle: 1.86 in septum, 2.25 in anterior wall, 1.41 in inferior wall, and 1.53 in lateral wall, respectively. These are in the expected range compared to previous studies. B 1 + maps show good signal uniformity around the position of the heart (0.13 ± 0.06 μT/sqrt(W)). Intrasession and intersession coefficients of reproducibility were 0.22–0.88 and 0.29–0.79, respectively. Linear modeling shows that regional PCr/γATP correlates with circumferential strain but not radial strain. This requires corroboration by a larger study including patients with impaired function and energetics. Conclusion: Dipole‐loop array coils present a promising new approach for human cardiac 31 P‐MRSI at 7 T. Their favorable B 1 + uniformity at depth and specific absorption rate over loop arrays and improved SNR when combined with loops for reception could be beneficial for further clinical studies measuring energetics by 31 P‐MRSI at 7 T. The new capability to assess PCr/γATP ratios across the whole left ventricle could enable clinical studies to investigate regional changes in cardiac energetics for the first time.
- 23 March 2025
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 94 (2) , 480-496
Open AccessRegionally resolved cardiac metabolism using a dipole‐loop array coil for 7 T 31 P ‐ MRSI
Purpose: We introduce a novel commercial phosphorus‐31 ( 31 P) dipole‐loop array coil, describing the coil hardware and testing its performance on phantoms. We used this coil to assess cardiac metabolism per region in healthy volunteers. Methods: B 1 + field maps were simulated and compared to maps measured with a set of CSI sequences with varying voltages. Seventeen volunteers were scanned with 7 T phosphorus‐31 magnetic resonance spectroscopic imaging ( 31 P‐MRSI). Reproducibility was assessed in nine of these volunteers. Strain was measured for six of these volunteers at 3 T. Results: Blood‐ and saturation‐corrected Phosphocreatine/γ‐adenosine triphosphate (PCr/ATP) ratios were measured for four regions of the left ventricle: 1.86 in septum, 2.25 in anterior wall, 1.41 in inferior wall, and 1.53 in lateral wall, respectively. These are in the expected range compared to previous studies. B 1 + maps show good signal uniformity around the position of the heart (0.13 ± 0.06 μT/sqrt(W)). Intrasession and intersession coefficients of reproducibility were 0.22–0.88 and 0.29–0.79, respectively. Linear modeling shows that regional PCr/γATP correlates with circumferential strain but not radial strain. This requires corroboration by a larger study including patients with impaired function and energetics. Conclusion: Dipole‐loop array coils present a promising new approach for human cardiac 31 P‐MRSI at 7 T. Their favorable B 1 + uniformity at depth and specific absorption rate over loop arrays and improved SNR when combined with loops for reception could be beneficial for further clinical studies measuring energetics by 31 P‐MRSI at 7 T. The new capability to assess PCr/γATP ratios across the whole left ventricle could enable clinical studies to investigate regional changes in cardiac energetics for the first time.
- Open Access
- 5 October 2023
- Published by Wiley in NMR in Biomedicine
- Vol. 36 (12) , e5031
Alteration of skeletal muscle energy metabolism assessed by 31P MRS in clinical routine: Part 2. Clinical application
In this second part of a two‐part paper, we intend to demonstrate the impact of the previously proposed advanced quality control pipeline. To understand its benefit and challenge the proposed methodology in a real scenario, we chose to compare the outcome when applying it to the analysis of two patient populations with significant but highly different types of fatigue: COVID‐19 and multiple sclerosis (MS). 31P‐MRS was performed on a 3 T clinical MRI, in 19 COVID‐19 patients, 38 MS patients, and 40 matched healthy controls. Dynamic acquisitions using an MR‐compatible ergometer ran over a rest (40 s), exercise (2 min), and a recovery phase (6 min). Long and short TR acquisitions were also made at rest for T1 correction. The advanced data quality control pipeline presented in Part 1 is applied to the selected patient cohorts to investigate its impact on clinical outcomes. We first used power and sample size analysis to estimate objectively the impact of adding the quality control score (QCS). Then, comparisons between patients and healthy control groups using the validated QCS were performed using unpaired t tests or Mann–Whitney tests (p < 0.05). The application of the QCS resulted in increased statistical power, changed the values of several outcome measures, and reduced variability (standard deviation). A significant difference was found between the T1PCr and T1Pi values of MS patients and healthy controls. Furthermore, the use of a fixed correction factor led to systematically higher estimated concentrations of PCr and Pi than when using individually corrected factors. We observed significant differences between the two patient populations and healthy controls for resting [PCr]—MS only, [Pi], [ADP], [H2PO4−], and pH—COVID‐19 only, and post‐exercise [PCr], [Pi], and [H2PO4−]—MS only. The dynamic indicators τPCr, τPi, ViPCr, and Vmax were reduced for COVID‐19 and MS patients compared with controls. Our results show that QCS in dynamic 31P‐MRS studies results in smaller data variability and therefore impacts study sample size and power. Although QCS resulted in discarded data and therefore reduced the acceptable data and subject numbers, this rigorous and unbiased approach allowed for proper assessment of muscle metabolites and metabolism in patient populations. The outcomes include an increased metabolite T1, which directly affects the T1 correction factor applied to the amplitudes of the metabolite, and a prolonged τPCr, indicating reduced muscle oxidative capacity for patients with MS and COVID‐19.
- 5 October 2023
- Published by Wiley in NMR in Biomedicine
- Vol. 36 (12) , e5031
Open AccessAlteration of skeletal muscle energy metabolism assessed by 31P MRS in clinical routine: Part 2. Clinical application
In this second part of a two‐part paper, we intend to demonstrate the impact of the previously proposed advanced quality control pipeline. To understand its benefit and challenge the proposed methodology in a real scenario, we chose to compare the outcome when applying it to the analysis of two patient populations with significant but highly different types of fatigue: COVID‐19 and multiple sclerosis (MS). 31P‐MRS was performed on a 3 T clinical MRI, in 19 COVID‐19 patients, 38 MS patients, and 40 matched healthy controls. Dynamic acquisitions using an MR‐compatible ergometer ran over a rest (40 s), exercise (2 min), and a recovery phase (6 min). Long and short TR acquisitions were also made at rest for T1 correction. The advanced data quality control pipeline presented in Part 1 is applied to the selected patient cohorts to investigate its impact on clinical outcomes. We first used power and sample size analysis to estimate objectively the impact of adding the quality control score (QCS). Then, comparisons between patients and healthy control groups using the validated QCS were performed using unpaired t tests or Mann–Whitney tests (p < 0.05). The application of the QCS resulted in increased statistical power, changed the values of several outcome measures, and reduced variability (standard deviation). A significant difference was found between the T1PCr and T1Pi values of MS patients and healthy controls. Furthermore, the use of a fixed correction factor led to systematically higher estimated concentrations of PCr and Pi than when using individually corrected factors. We observed significant differences between the two patient populations and healthy controls for resting [PCr]—MS only, [Pi], [ADP], [H2PO4−], and pH—COVID‐19 only, and post‐exercise [PCr], [Pi], and [H2PO4−]—MS only. The dynamic indicators τPCr, τPi, ViPCr, and Vmax were reduced for COVID‐19 and MS patients compared with controls. Our results show that QCS in dynamic 31P‐MRS studies results in smaller data variability and therefore impacts study sample size and power. Although QCS resulted in discarded data and therefore reduced the acceptable data and subject numbers, this rigorous and unbiased approach allowed for proper assessment of muscle metabolites and metabolism in patient populations. The outcomes include an increased metabolite T1, which directly affects the T1 correction factor applied to the amplitudes of the metabolite, and a prolonged τPCr, indicating reduced muscle oxidative capacity for patients with MS and COVID‐19.